It seems NSCLC is proving a somewhat thornier beast than the majors had perhaps anticipated.
If OS is the main game and Merck does want to roll Pembro/CVA-21 combo into something more substantial in NSCLC because of their superior OS experiences, I would like to think VLA will squeeze their goolies so they cough up for the right to play together.
Show me the money.
Keytruda and Merck article about problems with lung cancer trial., page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)